Ovid Q1 net loss $17M; raises $60M PIPE; dosed first OV4071 Phase 1; OV329 Phase 2 planned

Ovid Therapeutics Inc.

Q1 2026 net loss of $17.0M ($0.12/share) vs $10.2M loss ($0.14) in Q1 2025.
Cash $165.6M as of Mar 31, 2026; plus $27.3M in April from warrant exercises; runway into 2029.
Dosed first healthy volunteer in Phase 1 study of OV4071, oral KCC2 direct activator, for psychosis.
OV329 shows favorable safety/PK up to 9 mg; Phase 2 for focal onset seizures and TSC/infantile spasms planned.
Raised $60.0M gross from March 2026 PIPE and $53.9M from Series A warrant exercises (Oct 2025 PIPE).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ovid Therapeutics Inc. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 12, 2026, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing business updates and first quarter 2026 financial results.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Ovid Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-033859

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.